Comparative Pharmacology
Head-to-head clinical analysis: RISPERDAL versus UZEDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISPERDAL versus UZEDY.
RISPERDAL vs UZEDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Atypical antipsychotic; antagonist at dopamine D2 and serotonin 5-HT1A/5-HT2A receptors; partial agonist at serotonin 5-HT1A receptors
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
UZEDY (risperidone) extended-release injectable suspension: 75 mg, 100 mg, 150 mg, or 200 mg IM gluteal injection every 2 weeks after a single oral dose of 2 mg risperidone for 2 days; or 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, or 150 mg IM every 4 weeks after oral overlap for 2 days. Oral risperidone may be omitted if patient is stable on oral risperidone 2 mg/day.
None Documented
None Documented
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Terminal half-life approximately 30 days (range 23–37 days) after subcutaneous injection, supporting monthly dosing.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Primarily renal: 80% as metabolites, 1% unchanged. Biliary/fecal: 20%.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic